Umedeor is a technology company.
Umedeor has raised $17.6M across 3 funding rounds.
Umedeor has raised $17.6M in total across 3 funding rounds.
uMed (operating as Umedeor) is a healthtech company building a precision patient engagement and linked data access platform that accelerates clinical research and population health initiatives.[1][2][6] It serves pharmaceutical companies, academic researchers, healthcare professionals, institutions, and patients by rapidly identifying suitable patient cohorts from health records, automating tailored communications, collecting prospective and patient-reported data, and enabling revenue generation for GP practices through research participation.[1][6] The platform solves key challenges in clinical trials—like slow patient recruitment, high costs, and care gaps—by providing unique real-world evidence (RWE) combined with patient-generated data, supporting nationwide studies on conditions such as hypertension and Parkinson's risk.[1][6] With £9.8 million ($12.43 million total) raised in funding, uMed has expanded across the UK, US, and Canada, partnering with networks covering millions of patients and projecting access to over 10 million by late 2023.[1][3]
Founded in 2020 by Dr. Matt Wilson, an NHS doctor and anesthetist, uMed emerged from Wilson's recognition of inefficiencies in patient research and targeted care programs within the healthcare system.[1] The idea took shape to empower healthcare professionals to run studies and initiatives at scale, improving patient outcomes by closing care gaps and speeding up therapy development.[1] Early traction came via a seed round that same year, enabling successful UK-wide studies, including a precision medicine trial for high hypertension patients and a Parkinson's risk identification study.[1] Pivotal moments include a 2023 £9.8 million investment from investors like Delin Ventures, a Canadian partnership with MCI Onehealth, and embedding technology across provider networks in the UK, US, and Canada.[1]
uMed rides the wave of real-world evidence (RWE) and AI-driven precision medicine, capitalizing on post-pandemic demands for faster clinical trials amid regulatory pushes like the UK's O’Shaughnessy review advocating GP incentives.[1] Timing aligns with global healthtech growth, where inefficiencies in patient recruitment—often costing millions and delaying therapies—create tailwinds, especially as pharma seeks diverse, scalable data beyond traditional trials.[1][2] Market forces like expanding electronic health records and clinician-led partnerships favor uMed's model, influencing the ecosystem by democratizing research access for smaller providers and patients, fostering nationwide studies, and bridging evidence gaps in life sciences.[1][6]
uMed is poised for hypergrowth through its pipeline of health system deals and channel partners, potentially unlocking 10+ million patients and deeper pharma integrations.[1] Trends like AI-enhanced RWE, value-based care, and global trial decentralization will propel it, evolving its role from enabler to leader in population health platforms. As networks expand, expect heightened influence on therapy acceleration and provider economics, transforming how evidence gaps are closed in chronic disease research—building directly on its mission to mitigate care gaps at scale.[1][6]
Umedeor has raised $17.6M in total across 3 funding rounds.
Umedeor's investors include Albion VC, Kompas VC, Playfair Capital, Will Brooks, Will Martin, Eric Nadalin.
Umedeor has raised $17.6M across 3 funding rounds. Most recently, it raised $12.0M Series A in July 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2023 | $12.0M Series A | Albion VC, Kompas VC, Playfair Capital, Will Brooks, Will Martin | |
| Nov 1, 2020 | $5.0M Seed | Albion VC, Kompas VC, Playfair Capital, Will Brooks, Will Martin | |
| Mar 1, 2019 | $650K Seed | Kompas VC, Playfair Capital, Eric Nadalin, Will Brooks, Will Martin |